Amylyx Pharmaceuticals annual total assets
2021
2022
2023
2024
2025
Amylyx Pharmaceuticals Total Assets Growth & History (AMLX)
Amylyx Pharmaceuticals's total assets was $332.6M for fiscal 2025.
View full Amylyx Pharmaceuticals company overviewAmylyx Pharmaceuticals annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $332.6M | $139.0M | +71.79% |
| 2024 | 2024-12-31 | $193.6M | −$323.8M | −62.58% |
| 2023 | 2023-12-31 | $517.5M | $126.0M | +32.19% |
| 2022 | 2022-12-31 | $391.5M | $285.8M | +270.64% |
| 2021 | 2021-12-31 | $105.6M | — | — |
Amylyx Pharmaceuticals quarterly total assets
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $264.6M | $70.0M | +35.95% |
| Q1 2026 | 2026-03-31 | $293.6M | $73.9M | +33.65% |
| Q4 2025 | 2025-12-31 | $332.6M | $139.0M | +71.79% |
| Q3 2025 | 2025-09-30 | $362.7M | $112.0M | +44.68% |
| Q2 2025 | 2025-06-30 | $194.6M | −$137.6M | −41.41% |
| Q1 2025 | 2025-03-31 | $219.7M | −$197.8M | −47.38% |
| Q4 2024 | 2024-12-31 | $193.6M | −$323.8M | −62.58% |
| Q3 2024 | 2024-09-30 | $250.7M | −$215.9M | −46.27% |
| Q2 2024 | 2024-06-30 | $332.2M | −$121.4M | −26.77% |
| Q1 2024 | 2024-03-31 | $417.5M | $9.5M | +2.33% |
| Q4 2023 | 2023-12-31 | $517.5M | $126.0M | +32.19% |
| Q3 2023 | 2023-09-30 | $466.6M | $285.1M | +157.15% |
| Q2 2023 | 2023-06-30 | $453.6M | $228.3M | +101.38% |
| Q1 2023 | 2023-03-31 | $408.0M | $133.5M | +48.65% |
| Q4 2022 | 2022-12-31 | $391.5M | $285.8M | +270.64% |
| Q3 2022 | 2022-09-30 | $181.4M | — | — |
| Q2 2022 | 2022-06-30 | $225.2M | — | — |
| Q1 2022 | 2022-03-31 | $274.4M | — | — |
| Q4 2021 | 2021-12-31 | $105.6M | — | — |
Amylyx Pharmaceuticals total assets trends
Between the periods ended 2021-12-31 and 2025-12-31, Amylyx Pharmaceuticals's total assets increased from $105.6M to $332.6M, a change of $227.0M. The latest reported quarter, Q2 2026, shows $264.6M.
About the metric
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
Calculation and source
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Amylyx Pharmaceuticals source filings ↗